Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Gestational and Postpartum Weight Trajectories Among Women With and Without Asthma.

Go back to Resources

Gestational and Postpartum Weight Trajectories Among Women With and Without Asthma.

Authors:

Secondary:

Volume:

Issue:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.

Go back to Resources

Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.

Authors:

Secondary:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

Go back to Resources

Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

National Institute of Neurological Disorders and Stroke (NINDS) Common Data Elements (CDEs): Updates to the Stroke V1.0 Recommendations

Go back to Resources

National Institute of Neurological Disorders and Stroke (NINDS) Common Data Elements (CDEs): Updates to the Stroke V1.0 Recommendations

Authors:

URL:

Keywords:

Abstract:

Go back to Resources

Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.

Go back to Resources

Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.

Authors:

Secondary:

Volume:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

It’s not just what you do, it’s how you do it: Variation in substance use screening outcomes with commonly used screening approaches in primary care clinics

Go back to Resources

It’s not just what you do, it’s how you do it: Variation in substance use screening outcomes with commonly used screening approaches in primary care clinics

Authors:

URL:

Keywords:

Abstract:

Go back to Resources

Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).

Go back to Resources

Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).

Authors:

Secondary:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Change in Area of Intraretinal Macular Hemorrhages in Aflibercept- and Bevacizumab-treated Central Retinal and Hemiretinal Vein Occlusions: A SCORE2 Subanalysis

Go back to Resources

Change in Area of Intraretinal Macular Hemorrhages in Aflibercept- and Bevacizumab-treated Central Retinal and Hemiretinal Vein Occlusions: A SCORE2 Subanalysis

Authors:

Secondary:

Location:

URL:

Keywords:

Abstract:

Go back to Resources

The National Institute of Neurological Disorders and Stroke (NINDS) Updates to the Cerebral Palsy Common Data Elements Version 1.0 Recommendations

Go back to Resources

The National Institute of Neurological Disorders and Stroke (NINDS) Updates to the Cerebral Palsy Common Data Elements Version 1.0 Recommendations

Authors:

Secondary:

Location:

URL:

Keywords:

Abstract:

Go back to Resources

A Common Data Language for Clinical Research Studies: Overview and Update on the National Institute of Neurological Disorders and Stroke (NINDS) Common Data Element (CDE) Recommendations

Go back to Resources

A Common Data Language for Clinical Research Studies: Overview and Update on the National Institute of Neurological Disorders and Stroke (NINDS) Common Data Element (CDE) Recommendations

Authors:

Secondary:

Location:

URL:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Current page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification